Literature DB >> 25685650

Endoscopic endonasal surgery for recurrent pituitary tumors: technical challenges to the surgical approach.

Bobby A Tajudeen1, Jagmeet Mundi1, Jeffrey D Suh1, Marvin Bergsneider2, Marilene B Wang1.   

Abstract

Objective To review our experience in a series of patients who underwent revision endoscopic pituitary surgery. Methods Retrospective chart review. Results A total of 27 patients were included in the study. Of the 21 patients who required nasoseptal flap reconstruction, a left-sided nasoseptal flap was successfully used in 13 patients. Gross total or near-total resection of tumor was achieved in 74.1%. Cavernous sinus invasion and presentation with residual disease were identified as factors limiting extent of resection (p = 0.002 and 0.009, respectively). A statistically significant difference (p = 0.027) was noted between mean largest tumor dimension in patients with gross total resection and those with near-total or subtotal resection. Complications occurred in 22% and included postoperative temporary diabetes insipidus (n = 2), postoperative hypotension (n = 2), new anterior pituitary insufficiency (n = 1), and right-sided abducens palsy (n = 1). Conclusions Revision endoscopic pituitary surgery is advantageous but technically challenging. Cavernous sinus invasion and presentation with residual disease were significant factors limiting extent of resection. Suprasellar extension was not a factor limiting extent of resection and may prove to be an advantage over microscopic speculum-based approaches. Because of the right-sided scarring from prior surgery, a left-sided nasoseptal flap is reliable and advantageous.

Entities:  

Year:  2014        PMID: 25685650      PMCID: PMC4318731          DOI: 10.1055/s-0034-1383856

Source DB:  PubMed          Journal:  J Neurol Surg B Skull Base        ISSN: 2193-634X


  14 in total

1.  Endoscopic endonasal transsphenoidal surgery: experience with 50 patients.

Authors:  H D Jho; R L Carrau
Journal:  J Neurosurg       Date:  1997-07       Impact factor: 5.115

Review 2.  Recent results of secondary transnasal surgery for residual or recurring acromegaly.

Authors:  T Abe; D K Lüdecke
Journal:  Neurosurgery       Date:  1998-05       Impact factor: 4.654

3.  Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results.

Authors:  A Abosch; J B Tyrrell; K R Lamborn; L T Hannegan; C B Applebury; C B Wilson
Journal:  J Clin Endocrinol Metab       Date:  1998-10       Impact factor: 5.958

4.  Long-term follow-up of 'cured' prolactinoma patients after successful adenomectomy.

Authors:  E Ciccarelli; E Ghigo; C Miola; G Gandini; E E Muller; F Camanni
Journal:  Clin Endocrinol (Oxf)       Date:  1990-05       Impact factor: 3.478

5.  Trans-sphenoidal surgery of pituitary fossa tumors with televised radiofluoroscopic control.

Authors:  J Hardy; S M Wigser
Journal:  J Neurosurg       Date:  1965-12       Impact factor: 5.115

6.  Value of endoscopy for maximizing tumor removal in endonasal transsphenoidal pituitary adenoma surgery.

Authors:  Nancy McLaughlin; Amy A Eisenberg; Pejman Cohan; Charlene B Chaloner; Daniel F Kelly
Journal:  J Neurosurg       Date:  2012-12-14       Impact factor: 5.115

7.  Endoscopic transsphenoidal treatment in recurrent and residual pituitary adenomas--first experience.

Authors:  A Rudnik; T Zawadzki; B Gałuszka-Ignasiak; P Bazowski; I Duda; M Wojtacha; A I Rudnik; I Krawczyk
Journal:  Minim Invasive Neurosurg       Date:  2006-02

8.  Acromegaly.

Authors:  A L Barkan
Journal:  Trends Endocrinol Metab       Date:  1992-08       Impact factor: 12.015

Review 9.  Multimodality treatment for invasive pituitary adenomas.

Authors:  Mark Hornyak; William T Couldwell
Journal:  Postgrad Med       Date:  2009-03       Impact factor: 3.840

Review 10.  Update in pituitary disease.

Authors:  Shlomo Melmed
Journal:  J Clin Endocrinol Metab       Date:  2008-02       Impact factor: 5.958

View more
  7 in total

1.  Outcome of Endoscopic Transsphenoidal Surgery for Recurrent or Residual Pituitary Adenomas and Comparison to Non-Recurrent or Residual Cohort by Propensity Score Analysis.

Authors:  Xuan Gong; Yang Zhuo; Huichun Yuan; Kui Yang; Chuntao Li; Songshan Feng; Mingyu Zhang; Zhenyan Li; Hongshu Zhou; Zhixiong Liu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-04-25       Impact factor: 6.055

2.  An Algorithm for Sellar Reconstruction Following the Endoscopic Endonasal Approach: A Review of 300 Consecutive Cases.

Authors:  Edward C Kuan; Frederick Yoo; Pratik B Patel; Brooke M Su; Marvin Bergsneider; Marilene B Wang
Journal:  J Neurol Surg B Skull Base       Date:  2017-08-28

3.  Comparative study of complications after primary and revision transsphenoidal endoscopic surgeries.

Authors:  Leandro Custódio do Amaral; Baltazar Leão Reis; Antônio Ribeiro-Oliveira; Thamires Marx da Silva Santos; Alexandre Varella Giannetti
Journal:  Neurosurg Rev       Date:  2020-08-11       Impact factor: 3.042

Review 4.  Endoscopic Endonasal Versus Microscopic Transsphenoidal Surgery for Recurrent and/or Residual Pituitary Adenomas.

Authors:  Yoshua Esquenazi; Walid I Essayed; Harminder Singh; Elizabeth Mauer; Mudassir Ahmed; Paul J Christos; Theodore H Schwartz
Journal:  World Neurosurg       Date:  2017-02-06       Impact factor: 2.210

Review 5.  Thirty years of endoscopic sinus surgery: What have we learned?

Authors:  Bobby A Tajudeen; David W Kennedy
Journal:  World J Otorhinolaryngol Head Neck Surg       Date:  2017-01-21

Review 6.  Perioperative Considerations in Endoscopic Skull Base Surgery.

Authors:  Adnan S Hussaini; Christine M Clark; Timothy R DeKlotz
Journal:  Curr Otorhinolaryngol Rep       Date:  2020-03-19

7.  A Case of Giant Pituitary Adenoma Associated with a Postoperative Mental Disorder That Ultimately Resulted in Bilateral Blindness.

Authors:  Masahiro Tonari; Yuko Nishikawa; Junko Matsuo; Masashi Mimura; Hidehiro Oku; Jun Sugasawa; Naokado Ikeda; Yoshitaka Kurisu; Tsunehiko Ikeda
Journal:  Case Rep Ophthalmol       Date:  2020-03-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.